The Latest Analyst Ratings for Prelude Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Prelude Therapeutics (NASDAQ:PRLD) stock. The company has an average price target of $9.5, representing a 16.15% decrease from the previous average price target of $11.33. Two analysts have given bullish ratings, while two remained indifferent.
October 19, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Prelude Therapeutics has received mixed reviews from analysts, with an average price target of $9.5, indicating a potential decrease in stock price.
The average price target given by analysts is a key indicator of a stock's potential future performance. In this case, the average price target for PRLD has decreased, suggesting that analysts believe the stock price may decrease in the future. This could potentially have a negative impact on the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100